Medical News

RSS

Amid health bill delays and snags, lawmakers target issues

The wait for the Congressional Budget Office score on the Senate health care reform bill has left Senators with time to carefully consider all the angles on reform, The New York Times reports. Senate Majority Leader Harry Reid "has already received some substantial analysis of his measure, and if the numbers had been what he wanted, he would have released a bill by now.

16 Nov 2009

Carefx Fusionfx and Imprivata to provide integrated clinical access solution to Johns Hopkins Health System

Carefx Corporation, a leading provider of interoperable workflow solutions, and Imprivata®, Inc., the employee access management company, today announced that Johns Hopkins Health System, an internationally recognized group of healthcare institutions, has selected Carefx Fusionfx and Imprivata OneSign to deliver an integrated clinical access solution that streamlines access to workstations, applications and patient data. The complete, integrated system will launch in early 2010.

16 Nov 2009

Dyadic International reports financial results for the third quarter of 2009

Dyadic International, Inc. today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors’ report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic’s website at www.dyadic.com.

16 Nov 2009

Sentillion reaches milestone: More than 500,000 “live” caregivers use their solutions daily

Sentillion, whose identity and access management (IAM) solutions are the most widely implemented in healthcare, today announced that over 500,000 users are live and productively using its single sign-on and context management solutions. Leading healthcare organizations, ranging from single facilities to large, complex, multi-state health systems are part of a 160+ customer community that has deployed Sentillion’s IAM solutions enterprise-wide in over 1,000 hospitals.

16 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

16 Nov 2009

American Dental Partners to acquire certain non-clinical assets of Christie Dental

American Dental Partners, Inc. announced today that it has entered into an agreement to acquire certain non-clinical assets of Christie Dental Practice Group, P.L. and Christie Dental Partners, Inc. and enter into a 40-year service agreement with Christie Dental Practice Group, P.L.

16 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Migraine headaches linked with increased risk of common kind of stroke

Pooling results from 21 studies, involving 622,381 men and women, researchers at Johns Hopkins have affirmed that migraine headaches are associated with more than twofold higher chances of the most common kind of stroke: those occurring when blood supply to the brain is suddenly cut off by the buildup of plaque or a blood clot.

16 Nov 2009

Talend bags orders from several global healthcare customers

Talend, the recognized market leader in open source data integration software, today announced several global healthcare customer wins including Children’s Hospital & Medical Center of Omaha, Hosta, The Clermont-Ferrand Hospital and The University for Health Sciences, Medical Informatics and Technology (UMIT). The traction gained in this space further validates Talend’s ability to provide scalable and flexible solutions at an affordable cost to healthcare organizations of all sizes, while satisfying the need for the real-time data the industry demands.

16 Nov 2009

Eisai's LUSEDRA Injection now available for MAC sedation

Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

16 Nov 2009

Update from Novo Nordisk regarding its share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

16 Nov 2009

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the neuropathic pain drug market -- driven by the launches of several novel therapies -- will increase from $6 billion in 2008 to $9.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

16 Nov 2009

Bravo Health to open its first Advanced Care Center in Philadelphia

Bravo Health today announced that the first Bravo Health Advanced Care Center (the Center) will open in Philadelphia in January 2010. The Center, an innovative, state-of-the-art outpatient physician practice designed to meet the health care needs of Bravo Health members, will be located in a new building being constructed at 1010 W. Lehigh Avenue in North Philadelphia.

16 Nov 2009

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.

16 Nov 2009

Benenden selects Databarracks for online backup service

Benenden Hospital was founded in 1907 and became the centre for hospital treatment for members of Trade Unions and Friendly Societies and subsequently large numbers of public sector employees who joined what is now the Benenden Healthcare Society. The Society has over 900,000 member and nominee subscribers.

16 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Neogen's Board of Directors approves a 3-for-2 stock split

Neogen Corporation today announced that its Board of Directors has approved a 3-for-2 stock split. With the split, shareholders of record on Nov. 30, 2009, will receive one additional share of stock for each two shares held.

16 Nov 2009

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Researchers, decision makers, and people with HIV to attend Ontario HIV Treatment Network's conference

The 11th annual research conference of the Ontario HIV Treatment Network will examine the factors that increase risk for individuals and communities most affected by HIV, as well as interventions that may improve the lives of people living with HIV and prevent the spread of the virus.

16 Nov 2009

Medical News

Amid health bill delays and snags, lawmakers target issues

Carefx Fusionfx and Imprivata to provide integrated clinical access solution to Johns Hopkins Health System

Dyadic International reports financial results for the third quarter of 2009

Sentillion reaches milestone: More than 500,000 “live” caregivers use their solutions daily

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

American Dental Partners to acquire certain non-clinical assets of Christie Dental

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Migraine headaches linked with increased risk of common kind of stroke

Talend bags orders from several global healthcare customers

Eisai's LUSEDRA Injection now available for MAC sedation

Update from Novo Nordisk regarding its share repurchase programme

Decision Resources: Neuropathic pain drug market to be $9.7B in 2018

Bravo Health to open its first Advanced Care Center in Philadelphia

Semafore Pharmaceuticals to present SF1126 Phase I data at the 51st ASH meeting

Benenden selects Databarracks for online backup service

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Neogen's Board of Directors approves a 3-for-2 stock split

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Researchers, decision makers, and people with HIV to attend Ontario HIV Treatment Network's conference

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News